FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an anticancer drug containing a combination of 1-(3-C-ethinyl-β-D-ribopentifuranosyl)cytosine or its salt, and carboplatin. The invention also refers to the use of this combination for preparing the anticancer agent, a method of treating cancer which comprises administering the combination to the patient, and a method of enhancing the anticancer effect of carboplatin.
EFFECT: combination of 1-(3-C-ethinyl-β-D-ribopentifuranosyl)cytosine or its salt, and carboplatin provides the enhanced anticancer effect and the reduced unfavourable effects.
8 cl, 3 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR DRUG CONTAINING ANTITUMOUR PLATINUM COMPLEX, AND ANTITUMOUR EFFECT ENHANCER | 2015 |
|
RU2678103C2 |
| ANTITUMOUR AGENT CONTAINING CYTIDINE DERIVATIVE FOR CONTINUOUS INTRAVENOUS INTRODUCTION | 2008 |
|
RU2471486C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTITUMOR EFFECT WITH REDUCED ADVERSE EFFECTS AND CONTAINING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2214238C2 |
| APPLICATION OF ERIBULIN IN CANCER TREATMENT | 2015 |
|
RU2699545C2 |
| ANTITUMOR AGENT, ANTITUMOR ENHANCER AND ANTITUMOR KIT | 2017 |
|
RU2752172C2 |
| COMBINED ANTICANCER THERAPY AND PHARMACEUTICAL COMPOSITIONS THEREFOR | 2005 |
|
RU2396960C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
